Reports Q3 revenue $37.140M, consensus $32.79M. “This was another productive quarter across the company – we were pleased to announce the closing of the Telavant transaction with Roche in December. I am proud of our continued progress in clinical development, with another positive result generated by the Immunovant team in Graves’ disease. The positive initial data continues to support our view of the broad applicability of FcRn and the potentially meaningful clinical benefits associated with deeper IgG suppression,” said Matt Gline, CEO of Roivant. “Looking ahead, we are excited about multiple upcoming clinical data readouts and other catalysts expected this year, as well as the prospect of expanding our clinical pipeline. 2024 will be a year of growth for Roivant.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ROIV:
- Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
- ROIV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Jefferies ‘encouraged thus far’ by Arbutus patent hearing
- JPMorgan biotech analysts to hold an analyst/industry conference call
- Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024